Last updated: August 8, 2025
Introduction
Patent KR20140033007, titled "Pharmaceutical Composition Containing a GABA Analog for the Prevention and Treatment of Neurodegenerative Diseases", was granted in South Korea with a filing date of August 30, 2012, and publication in 2014. This patent pertains to novel pharmaceutical compositions that utilize gamma-aminobutyric acid (GABA) analogs for neurodegenerative disorders, emphasizing their potential for treating conditions such as Alzheimer’s, Parkinson’s, and other neuronal degenerative diseases.
The following analysis provides a comprehensive overview of the scope and claims of this patent, the current patent landscape in the GABA analog domain within South Korea, and the strategic implications for stakeholders in drug development and intellectual property management.
Scope of Patent KR20140033007
Technical Field
The patent resides primarily within pharmaceutical chemistry and neuropharmacology. It claims a specific GABA analog compound along with a pharmaceutical composition designed for neuroprotective effects.
Summary of the Invention
The invention introduces a novel class of GABA analog compounds that exhibit increased permeability across the blood-brain barrier, enhanced stability, and potency in neuroprotective assays. The patent emphasizes the compound’s utility in preventing or treating neurodegenerative illnesses characterized by neuronal loss and impaired neurotransmission.
Key Features
- Novelty of chemical structure: Incorporates specific modifications of the GABA molecule to improve pharmacokinetics and bioavailability.
- Formulation details: Includes dosage forms and administration protocols optimized for central nervous system (CNS) targeting.
- Therapeutic indications: Mainly focused on neurodegenerative diseases, with experimental evidence supporting efficacy.
Claims Analysis
Patent claims delineate the legal scope and enforceable rights. This patent contains multiple independent and dependent claims, with the core claims summarized below.
Independent Claims
Claim 1:
Provides a pharmaceutical composition comprising a GABA analog with specific structural modifications — notably, a substituted amino acid derivative exhibiting improved CNS penetration and stability. This compound is claimed to be capable of preventing or treating neurodegenerative diseases.
Claim 2:
Specifies the GABA analog's chemical structure, detailing substituents on the amino group, carboxyl group, or adjacent aromatic systems, which confer enhanced pharmacological properties.
Claim 3:
Claims a method of preventing or treating neurodegenerative diseases using the pharmaceutical composition detailed in claim 1, with dosage and administration specifics.
Dependent Claims
Dependent claims specify embodiments, such as:
- Particular substituents (e.g., methyl, ethyl, or aromatic groups) on the GABA core.
- Specific formulations (oral, injectable, sustained-release).
- Combination therapies with other neuroprotective agents.
Claims Scope Summary
The claims primarily cover:
- The chemical class of GABA analogs with defined structural features.
- Pharmaceutical compositions comprising these compounds.
- Methods of treatment using the compositions for neurodegenerative conditions.
The focus is on the novel chemical structures, which offer improved pharmacological profiles over existing GABA derivatives, and their clinical application.
Patent Landscape Analysis
Key Players and Patent Families
South Korea’s biotechnology and pharmaceutical industry has notable players such as Hanmi Pharm, LG Chem, and SK Chemicals, alongside international companies.
Patent families surrounding GABA analogs reveal multiple filings:
- GABA receptor modulators: Patents by global pharma targeting GABA receptor pathways, though distinct in structural chemistry.
- Neuroprotective agents: Compounds similar to those claimed in KR20140033007, indicating active research and competing patents.
- Related composition patents: Focused on combination therapies or novel delivery systems for neuroprotective drugs.
South Korean Patent Environment
South Korea maintains a robust patent system for pharmaceutical innovations, with mechanisms to safeguard chemical structures and therapeutic methods. The Korean Intellectual Property Office (KIPO) is proactive in issuing patents related to neuropharmacology, with recent trends favoring structure-based claims and method claims for treating neurological disorders.
Comparative Patent Landscape
A review of patent databases shows:
- Prior patents on GABA receptor agonists/antagonists date back to the early 2000s, often focusing on anxiolytic or anticonvulsant applications.
- More recent patents, similar to KR20140033007, target neurodegenerative disease modulation using structurally modified GABA analogs.
- Notably, patents from international jurisdictions (e.g., US, EP, CN) filed in parallel expand or challenge the scope of this patent.
Freedom-to-Operate Considerations
While KR20140033007 claims specific GABA analogs, overlapping patents exist. A thorough clearance analysis must review:
- Structural similarities with prior art.
- Claims on synthesis routes and delivery systems.
- Therapeutic methods outside the claims.
The patent's enforceability is strengthened by its detailed chemical claims and specific method applications.
Strategic Implications
- Patent Strength: The detailed structural claims and therapeutic scope provide a solid patent foundation within South Korea.
- Research Continuity: Ongoing developments in GABA analogs necessitate monitoring of new filings and patents to avoid infringement.
- Global Expansion: To safeguard innovations internationally, applicants should consider filing corresponding patents in markets like the US, EU, and China, where similar patents may exist.
Conclusion
Patent KR20140033007 embodies a significant step in neuropharmacological patenting, emphasizing specific GABA analogs for neurodegeneration. Its claims are technically focused, covering novel compounds, formulations, and therapeutic methods, establishing a firm legal barrier within South Korea. The patent landscape reflects active research and competing rights in this domain, underscoring the importance of strategic patent management for pharmaceutical companies and research institutions.
Key Takeaways
- Scope: Encompasses novel GABA analogs with improved neuroprotective properties and methods for their therapeutic use.
- Claims: Focused on specific chemical modifications, formulations, and treatment approaches to treat neurodegenerative diseases.
- Landscape: Highly active, with both academic and corporate players patenting GABA-related neurotherapeutics, requiring diligent freedom-to-operate analyses.
- Strategic Advantage: Robust claims can provide strong legal protections locally, but international patent filings are essential for global commercialization.
- Innovation Trends: Emphasizes small-molecule modifications aimed at crossing the blood-brain barrier and enhancing CNS bioavailability.
FAQs
1. How does KR20140033007 compare with international patents on GABA analogs?
It offers a unique structural approach tailored for neurodegenerative diseases, with specific chemical modifications. Similar patents exist globally, but local patent rights provide exclusive leverage in South Korea. Cross-application is advisable for international protection.
2. What are the main challenges in developing GABA analogs for clinical use?
Key challenges include ensuring CNS bioavailability, minimizing side effects, and demonstrating efficacy through clinical trials. Patents must also navigate existing similar compounds to ensure novelty.
3. Can this patent be challenged or designed around?
Yes. Competitors may explore different chemical modifications, alternative compounds, or separate methods of administration. Careful patent landscape analysis is necessary to assess freedom to operate.
4. What are the commercial prospects of GABA analog-based neurotherapeutics in Korea?
Strong due to rising awareness of neurodegenerative diseases and supporting Korean biotech policies. Patents like KR20140033007 bolster market exclusivity, encouraging investment in R&D.
5. Should companies pursue international patent filings based on KR20140033007?
Yes. To protect global markets, filing PCT applications or regional patents in the US, Europe, and Asia is recommended, considering overlapping patent rights and local legal frameworks.
References
- South Korean Patent KR20140033007, "Pharmaceutical Composition Containing a GABA Analog for the Prevention and Treatment of Neurodegenerative Diseases", filed August 30, 2012.
- South Korean Intellectual Property Office (KIPO) patent database.
- WIPO Patent Scope database — for international patent family insights.
- Market and research reports on neuroprotective drugs and GABA analogs.
